A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
Johnson
Tam Spitzer
TS
Shands Teaching Hospital, Occupational Health Services, Gainesville, Florida, USA. spitzm@shands.ufl.edu
D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001521:Behavior Therapy; D001552:Benzazepines / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D006801:Humans; D009538:Nicotine; D018722:Nicotinic Agonists / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D012307:Risk Factors; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D019966:Substance-Related Disorders / Q000235:genetics / Q000451:nursing; D000068580:Varenicline
D018687:Antidepressive Agents, Second-Generation; D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline